-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cowen Boosts FibroGen (NASDAQ:FGEN) Price Target to $14.00
Cowen Boosts FibroGen (NASDAQ:FGEN) Price Target to $14.00
FibroGen (NASDAQ:FGEN – Get Rating) had its price objective boosted by stock analysts at Cowen to $14.00 in a research report issued on Monday, Stock Target Advisor reports. Cowen's price target suggests a potential downside of 4.04% from the stock's current price.
A number of other equities research analysts have also recently commented on the stock. StockNews.com cut shares of FibroGen from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th. The Goldman Sachs Group reduced their target price on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a report on Tuesday, May 24th.
Get FibroGen alerts:FibroGen Stock Up 0.7 %
FGEN traded up $0.10 on Monday, reaching $14.59. The company had a trading volume of 424,401 shares, compared to its average volume of 876,948. The stock has a 50-day moving average price of $11.91 and a 200-day moving average price of $11.98. FibroGen has a 1 year low of $7.81 and a 1 year high of $16.91. The stock has a market capitalization of $1.37 billion, a PE ratio of -6.16 and a beta of 0.87.
FibroGen (NASDAQ:FGEN – Get Rating) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.16. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The business had revenue of $29.81 million during the quarter, compared to analysts' expectations of $36.15 million. During the same period in the prior year, the company earned ($1.45) earnings per share. The business's revenue was up 22.3% compared to the same quarter last year. As a group, analysts expect that FibroGen will post -3 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in shares of FibroGen by 369.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,795 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 2,200 shares during the period. Quantbot Technologies LP acquired a new position in shares of FibroGen during the second quarter worth about $39,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in shares of FibroGen during the first quarter worth about $59,000. Lazard Asset Management LLC acquired a new position in shares of FibroGen during the second quarter worth about $59,000. Finally, Advisor Group Holdings Inc. increased its stake in shares of FibroGen by 90.6% during the fourth quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock worth $130,000 after acquiring an additional 4,236 shares during the period. 77.35% of the stock is currently owned by institutional investors and hedge funds.
FibroGen Company Profile
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- The Institutions Trim Holdings Of High-Yielding Foot Locker, Inc
- Here's How the Inflation Reduction Act Energizes Power Stock
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
FibroGen (NASDAQ:FGEN – Get Rating) had its price objective boosted by stock analysts at Cowen to $14.00 in a research report issued on Monday, Stock Target Advisor reports. Cowen's price target suggests a potential downside of 4.04% from the stock's current price.
据Stock Target Advisor报道,考恩的股票分析师在周一发布的一份研究报告中将FibroGen(纳斯达克:FDEN-GET评级)的目标价上调至14.00美元。考恩的目标价表明,该股目前的价格可能下跌4.04%。
A number of other equities research analysts have also recently commented on the stock. StockNews.com cut shares of FibroGen from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th. The Goldman Sachs Group reduced their target price on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a report on Tuesday, May 24th.
其他一些股票研究分析师最近也对该股发表了评论。在8月10日星期三的一份报告中,StockNews.com将FibroGen的股票评级从“买入”下调至“持有”。高盛夫妇将FibroGen的股票目标价从9.00美元下调至8.00美元,并在5月24日(星期二)的一份报告中为该公司设定了“卖出”评级。
FibroGen Stock Up 0.7 %
FibroGen股价上涨0.7%
FGEN traded up $0.10 on Monday, reaching $14.59. The company had a trading volume of 424,401 shares, compared to its average volume of 876,948. The stock has a 50-day moving average price of $11.91 and a 200-day moving average price of $11.98. FibroGen has a 1 year low of $7.81 and a 1 year high of $16.91. The stock has a market capitalization of $1.37 billion, a PE ratio of -6.16 and a beta of 0.87.
周一,fgen的交易价格上涨了0.1美元,达到14.59美元。该公司的成交量为424,401股,而其平均成交量为876,948股。该股的50日移动均线价格为11.91美元,200日移动均线价格为11.98美元。FibroGen的一年低点为7.81美元,一年高位为16.91美元。该股市值13.7亿美元,市盈率为-6.16,贝塔系数为0.87。
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in shares of FibroGen by 369.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,795 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 2,200 shares during the period. Quantbot Technologies LP acquired a new position in shares of FibroGen during the second quarter worth about $39,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in shares of FibroGen during the first quarter worth about $59,000. Lazard Asset Management LLC acquired a new position in shares of FibroGen during the second quarter worth about $59,000. Finally, Advisor Group Holdings Inc. increased its stake in shares of FibroGen by 90.6% during the fourth quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock worth $130,000 after acquiring an additional 4,236 shares during the period. 77.35% of the stock is currently owned by institutional investors and hedge funds.
机构投资者和对冲基金最近对他们在该公司的头寸进行了调整。NISA Investment Advisors LLC在第二季度增持了369.7%的FibroGen股票。NISA Investment Advisors LLC现在持有这家生物制药公司2,795股股票,价值30,000美元,在此期间又购买了2,200股。Quantbot Technologies LP在第二季度收购了FibroGen股票的新头寸,价值约3.9万美元。Dixon Hughes Goodman Wealth Advisors LLC在第一季度收购了FibroGen股票的新头寸,价值约59,000美元。Lazard Asset Management LLC在第二季度收购了FibroGen股票的新头寸,价值约5.9万美元。最后,Advisor Group Holdings Inc.在第四季度增持了90.6%的FibroGen股票。Advisor Group Holdings Inc.在此期间增持了4,236股,目前持有这家生物制药公司8,909股股票,价值130,000美元。77.35%的股票目前由机构投资者和对冲基金持有。
FibroGen Company Profile
FibroGen公司简介
(Get Rating)
(获取评级)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen,Inc.是一家生物制药公司,发现、开发和商业化治疗严重未得到满足的医疗需求的疗法。该公司正在开发一种口服低氧诱导因子Pro羟基酶小分子抑制剂roxadustat,该药已在美国、欧洲、中国和日本完成了治疗慢性肾脏疾病贫血的第三阶段临床开发,并在中国完成了治疗与骨髓增生异常综合征相关的贫血的第二/第三阶段临床开发。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- The Institutions Trim Holdings Of High-Yielding Foot Locker, Inc
- Here's How the Inflation Reduction Act Energizes Power Stock
- 免费获取StockNews.com关于FibroGen的研究报告(Fgen)
- 第二季度财报季最热门的五个电话
- 以下是一个简单的4只股票投资组合,它可以跑赢大盘
- AMC娱乐公司是在对猩猩采取快速行动吗?
- 机构调整高收益Foot Locker,Inc.的控股
- 以下是《降低通胀法案》如何提振电力库存
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对FibroGen和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧